Summary

Cangrelor, an intravenous, potent, direct-acting adenosine diphosphate (ADP) receptor antagonist, significantly reduced the composite endpoint of death, myocardial infarction (MI), ischemia-driven revascularization, and stent thrombosis in patients undergoing percutaneous coronary intervention (PCI) with no excess in severe bleeding compared with clopidogrel loading at the time of PCI. This article presents the results of the Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [CHAMPION PHOENIX; Bhatt DL et al. N Engl J Med 2013] in a late-breaking clinical trial.